Sonnet BioTherapeutics I... (SONN)
| Bid | 1.5 |
| Market Cap | 4.72M |
| Revenue (ttm) | 1.67M |
| Net Income (ttm) | -14.29M |
| EPS (ttm) | -10.45 |
| PE Ratio (ttm) | -0.15 |
| Forward PE | -0.12 |
| Analyst | Buy |
| Ask | 1.6 |
| Volume | 28,047 |
| Avg. Volume (20D) | 1,057,708 |
| Open | 1.53 |
| Previous Close | 1.54 |
| Day's Range | 1.48 - 1.54 |
| 52-Week Range | 1.38 - 18.72 |
| Beta | 1.03 |
About SONN
Sonnet BioTherapeutics Holdings, Inc., a clinical stage oncology-focused biotechnology company, develops platform for biologic medicines of single or bispecific action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead candidate is SON-1010, a fully human version of interleukin 12 for the ...
Analyst Forecast
According to 2 analyst ratings, the average rating for SONN stock is "Buy." The 12-month stock price forecast is $38, which is an increase of 2367.53% from the latest price.
10 months ago · newsfilecorp.com
Sonnet BioTherapeutics Announces Participation in the EF Hutton Annual Global ConferenceMinneapolis, Minnesota--(Newsfile Corp. - May 3, 2024) - Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN), a biopharmaceutical company developing innovative targeted biologic drugs, will be partic...
